Low-dose IL-2 promotes immune regulation in face transplantation: A pilot study.
暂无分享,去创建一个
C. Lian | S. Sui | B. Pomahac | R. Clark | E. Bueno | L. Riella | T. Borges | P. Abarzua | G. Murphy | S. Tasigiorgos | J. Teague | N. Murakami | T. Win | Victor Barrera | B. Kollár
[1] A. Douiri,et al. Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans. , 2022, Journal of hepatology.
[2] A. Bharat,et al. Low‐dose IL‐2 prevents murine chronic cardiac allograft rejection: Role for IL‐2‐induced T regulatory cells and exosomes with PD‐L1 and CD73 , 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[3] Shannan J. Ho Sui,et al. Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection. , 2021, The Journal of clinical investigation.
[4] M. Gavin,et al. An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice , 2020, Science Immunology.
[5] Jason D. Buenrostro,et al. ImmGen at 15 , 2020, Nature Immunology.
[6] James A. Hutchinson,et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials , 2020, The Lancet.
[7] J. Bluestone,et al. Treg cell-based therapies: challenges and perspectives , 2019, Nature Reviews Immunology.
[8] B. Pomahac,et al. Five-Year Follow-up after Face Transplantation. , 2019, The New England journal of medicine.
[9] J. Todd,et al. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease , 2018, Journal of autoimmunity.
[10] A. Loupy,et al. Antibody-Mediated Rejection of Solid-Organ Allografts. , 2018, The New England journal of medicine.
[11] M. Parkes,et al. Mechanistic Sharing Between NK Cells in ABMR and Effector T Cells in TCMR , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[12] M. Sarwal,et al. Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] I. Macdougall,et al. IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors , 2017, Proceedings of the National Academy of Sciences.
[14] L. Riella,et al. Treg‐Centric View of Immunosuppressive Drugs in Transplantation: A Balancing Act , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[15] X. Jouven,et al. Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection , 2017, Circulation.
[16] Hongye Liu,et al. Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. , 2016, JCI insight.
[17] E. Morand,et al. Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus , 2016, Nature Medicine.
[18] J. Ritz,et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. , 2016, Blood.
[19] Jeffrey A. Bluestone,et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells , 2015, Science Translational Medicine.
[20] R. Wiseman,et al. Sequential Monitoring and Stability of Ex Vivo–Expanded Autologous and Nonautologous Regulatory T Cells Following Infusion in Nonhuman Primates , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[21] R. Locksley,et al. Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. , 2014, Blood.
[22] Piero Carninci,et al. Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific transcriptional regulation , 2014, Proceedings of the National Academy of Sciences.
[23] J. Ritz,et al. Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease , 2013, Science Translational Medicine.
[24] A. Le Moine,et al. Impact of interleukin-2-expanded regulatory T cells in various allogeneic combinations on mouse skin graft survival. , 2012, Transplantation proceedings.
[25] A. Kirk,et al. Regulatory T Cells Exhibit Decreased Proliferation but Enhanced Suppression After Pulsing With Sirolimus , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[26] T. Strom,et al. Prolonged Survival of Allogeneic Islets in Cynomolgus Monkeys After Short‐Term Triple Therapy , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[27] F. Carrat,et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. , 2011, The New England journal of medicine.
[28] J. Ritz,et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.
[29] P. Halloran,et al. Diagnosing Rejection in Renal Transplants: A Comparison of Molecular‐ and Histopathology‐Based Approaches , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[30] J. Sprent,et al. In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression , 2009, The Journal of experimental medicine.
[31] I. Türbachova,et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells , 2007, European journal of immunology.
[32] V. Kuchroo,et al. Contrasting Effects of Cyclosporine and Rapamycin in De Novo Generation of Alloantigen‐Specific Regulatory T Cells , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[33] D. Valmori,et al. Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells1 , 2006, The Journal of Immunology.